Supernus Pharmaceuticals | SUPN - Przychody Ze Sprzedaży





Obroty Zmiana Data
Abbott USD 11.16B 300M 2026-03
ANI Pharmaceuticals USD 247.06M 19.25M 2025-12
Aurora Cannabis CAD 94.19M 3.82M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Canopy Growth CAD 74.54M 7.86M 2025-12
Cara Therapeutics USD 2.57M 1.11M 2025-03
Corcept Therapeutics USD 202.12M 5.48M 2025-12
Eisai JPY 219.94B 22.58B 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Novo Nordisk DKK 79.14B 4.16B 2025-12
Pacira USD 196.87M 17.35M 2025-12
Perrigo USD 1.11B 70M 2025-12
Pfizer USD 17.58B 880M 2025-12
Supernus Pharmaceuticals USD 211.6M 19.5M 2025-12
United Therapeutics USD 790.2M 9.3M 2025-12
Xeris Pharmaceuticals USD 85.81M 11.43M 2025-12